Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2013 Sep 1;23(17):4741-50. doi: 10.1016/j.bmcl.2013.07.006. Epub 2013 Jul 12.

A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.

Author information

1
Public Health Research Institute, New Jersey Medical School, Newark, NJ, United States.

Abstract

Tuberculosis is a bacterial disease that predominantly affects the lungs and results in extensive tissue pathology. This pathology contributes to the complexity of drug development as it presents discrete microenvironments within which the bacterium resides, often under conditions where replication is limited and intrinsic drug susceptibility is low. This consolidated pathology also results in impaired vascularization that limits access of potential lead molecules to the site of infection. Translating these considerations into a target-product profile to guide lead optimization programs involves implementing unique in vitro and in vivo assays to maximize the likelihood of developing clinically meaningful candidates.

KEYWORDS:

Drug discovery; Tuberculosis

PMID:
23910985
PMCID:
PMC3789655
DOI:
10.1016/j.bmcl.2013.07.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center